One study showed that CCR2 blockade by a CCR2 antagonist in vivo decreased the number of M2 macrophages, increased the number of IFNγ + CD8 + T cells, and inhibited tumor growth, indicating that M2 macrophage-mediated indirect effects significantly affect tumor growth [35]. Here, CD8A is linked to neoplasm.